BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update

Go back to BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update

Brainstorm Cell Therapeutics (BCLI) Reports Q2 Loss of $0.16/Share

July 23, 2018 8:06 AM EDT

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.16), versus ($0.06) reported last year.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

... More